OOIR: Observatory of International Research

Papers

(The median citation count of Expert Opinion on Drug Safety is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	132
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	125
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	99
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	51
Safety concerns associated with various types of statins: a disproportionality analysis of the FAERS database	46
The safety of phthalate-containing medications used during pregnancy	42
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	39
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	39
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	36
Why is pharmacovigilance essential for biosimilars?	35
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	35
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	33
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	32
The role of artificial intelligence in pharmacovigilance for rare diseases	28
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies	28
An updated safety review of Hidradenitis Suppurativa treatment options	26
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	26
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	26
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	25
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	25
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	25
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	24
Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis	22
Safety concerns associated with BACE1 inhibitors – past, present, and future	22
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients	22

Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system	22
The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis	21
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database	20
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis	20
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy	20
The Impact of Medication Regimen Complexity Score on Multi-Organ Dysfunction and Clinical Outcomes in Critically Ill Patients: A Cohort Study	20
Risk of acute kidney injury in patients receiving vancomycin and concomitant piperacillin-tazobactam or carbapenem: a multicenter, retrospective cohort study	20
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS	18
Safety and efficacy of anticoagulant administration in people with atrial fibrillation and advanced chronic kidney disease	18
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study	17
Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system	17
Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system	17
Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023	17
Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases	17
Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database	17
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?	17
Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveil	16
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treat	16
Correction	16
A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data	16
Comparative analysis of CDKI-related adverse events in older patients: a real-world data from the FDA adverse event reporting system database	16
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review	15
Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits	15
SSRI withdrawal syndrome in children and adolescents: a narrative literature review	15
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database	14
Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System	14
Development and validation of a nomogram to predict the risk of potentially inappropriate medication use in older lung cancer outpatients with multimorbidity	14
Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FD	14
Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database	14
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!	14
Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis	14
Current safety concerns about the use of antiseizure medications in pregnancy	14
Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database	14
Exploration of the clinical characteristics and potential mechanisms of liver injury induced by proton pump inhibitors	13
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system	13
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	13
Biologic and targeted synthetic therapies in juvenile idiopathic arthritis: a review of current and emerging therapeutic agents	13
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge	13
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database	13
Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database	12
Safety considerations for drugs newly approved for treating acute myeloid leukemia	12
Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience	12
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)	12
Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system	12
GLP-1-derived therapies and risk of sarcopenia: myth or reality?	12
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database	12
Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases	12
How do safety warnings on medicines affect prescribing?	12
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database	11
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database	11

Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERS	11
The effectiveness and safety of naldemedine in treating opioid-induced constipation among non-cancer adult patients: updated meta-analysis	11
Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database	11
Vancomycin and linezolid: severe cutaneous adverse reactions to drugs	11
Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment	11
Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database	11
Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database	10
Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis	10
The importance and utility of post market drug safety monitoring in cancer therapy	10
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database	10
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network	10
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis	10
Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system	10
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database	10
Short-acting beta 2 agonists overuse in asthma: where are we now?	10
Treating psychosis in people with Parkinson’s disease	10
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies	10
Will the future of pharmacovigilance be more automated?	10
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)	9
Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception	9
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab	9
Reply to Letter to the Editor regarding “Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database”	9
What’s in a name? What shall we call xanomeline-trospium combination?	9
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database	9
Are the current safety measures for the treatment of depression with esketamine sufficient?	9
Biosimilars and immunogenicity: a matter of concern?	9
Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases	9
Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis	9
The Safety, Efficacy, and Clinical Use of Novel Once-Weekly Insulins in the Management of Diabetes	9
Detection of risk signals for ustekinumab in the real world using the FDA Adverse Event Reporting System (FAERS)	9
Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database	9
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)	9
Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system	8
Risk factors analysis and construction of predictive models for acute kidney injury in overweight patients receiving vancomycin treatment	8
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests	8
Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database	8
Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis	8
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases	8
Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East	8
Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database	8
Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer	8
Effects of adding adjuvants to propofol on the post-anesthesia cognitive function in patients undergoing gastroscopy/colonoscopy: a systematic review and meta-analysis	8
Chronic sequelae of immune-related adverse events	8
Study on analgesic-induced endocrine gland damage and its potential mechanisms	8
Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors	8
The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands	8
Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database	8
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis	8
COVID-19 vaccine safety studies- the need for a third group for extended monitoring	8
Drug-induced dementia: a pharmacovigilance analysis of the FAERS database	8
A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective	8
Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database	7
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System databas	7
Contributory factors and patient harm including deaths associated direct acting oral anticoagulants (DOACs) medication incidents: evaluation of real world data reported to the National Reporting and L	7
The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials	7
Tirzepatide data: safety always comes first!	7
Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database	7
COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formula	7
An update on the safety of ixazomib for the treatment of multiple myeloma	7
Dupilumab in real-life settings: a review of adverse events and their pathogenesis	7
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior lite	7
Definition of treatment resistant psoriasis and related safety concerns	7
Oral isotretinoin for acne: a complete overview	7
Correction	7
Postmarketing safety of [ ¹⁷⁷ Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system	7
Safe prescribing of antihypertensive drugs in the elderly and managing the risk of adverse events	7
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	7
Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System	7
Safety of medications for hereditary angioedema during pregnancy and lactation	7
Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database	7
Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)	7
Drug-induced nephrolithiasis: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System	7
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	7
Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS	6
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database	6
The safety and efficacy of sugammadex for reversing neuromuscular blockade in younger children and infants	6
Incidence, clinical characteristics and related drugs analyzing of drug-induced movement disorders in 102914 inpatients: a retrospective real-world study	6
Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice	6
Post-marketing safety of panitumumab: a real-world pharmacovigilance study	6
A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence – what have we learned recently?	6

A retrospective study to evaluate Hy’s Law, DrILTox ALF score, Robles-Diaz model, and a new logistic regression model for predicting acute liver failure in Chinese patients with drug-induced liver inj	6
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and toler	6
Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database	6
Comparison of safety of acetaminophen and ibuprofen in minors: based on the FAERS database	6
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database	6
The safety of available pharmacotherapy for stroke prevention in atrial fibrillation	6
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia	6
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system	6
Letter to the Editor in response to: “Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database”	6
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study	6
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review	6
Pre- and post-operative safety considerations for patients undergoing percutaneous nephrolithotomy	6
Management of refractory checkpoint inhibitor-induced colitis	6
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis	6
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024	6
Analyzing the patterns of adverse drug reactions due to anti-infectives from large-scale nationwide database in Thailand	6
Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)	6
The impact of the COVID-19 pandemic on adverse events associated with ACEIs and ARBs: a real-world analysis using the FDA adverse event reporting system	6
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database	6
Approved treatments for neovascular age-related macular degeneration: current safety and future directions	6
A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system	6
Safeguarding drug safety in neonates: addressing the impact of in-hospital medication administration errors through prevention and standardization	6
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study	5
Rare irAEs associated with immune checkpoint inhibitor therapy	5
Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database	5
Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system	5
Safety of PARP inhibitors as maintenance therapy in ovarian cancer	5
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database	5
A real-world pharmacovigilance case/non-case study of FDA adverse event reporting system events for mannitol	5
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trials	5
Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)	5
Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial	5
Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database	5
Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related	5
Anaphylactic risk associated with iodinated and gadolinium-based contrast media	5
Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention	5
Influence of prior treatment protocol on intravitreal dexamethasone implant behavior in patients with diabetic macular edema in real-world practice	5
Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis	5
Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database	5
Correction	5
Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database	5
Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation	5
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis	5
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)	5
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database	5
Bridging evidence gaps in dravet syndrome: real-world safety insights from under-reported antiseizure therapies	5
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database	5
Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review	5
Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database	5
Adverse effects associated with antipsychotic use in older adults	5
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis	5
Actual drug-related harms in residential aged care facilities: a narrative review	5
Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database	5
Venous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect?	5
Serotonin 5-HT _2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	5
An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting	5
Risk of serious skin and subcutaneous tissue disorders for nimesulide among the pediatric population: a jeopardy identified through the analysis of global individual case safety reports	5
Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events	5
Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014–2022)	5
New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China	5
Neural dysfunction, inflammatory disorder, and metabolic interference feature in amantadine-related adverse drug events: a perspective from FAERS and network toxicology	5
Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?	5
Appropriateness of psychopharmacological therapies to psychiatric diagnoses in persons with autism spectrum disorder with or without intellectual disabilities: a cross-sectional analytic study	5
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases	5
Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)	5
Identification of novel signal of Raynaud’s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches	5
Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database	5
Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system	5
Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature	5
Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS	5
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	5
Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis	4
Assessment of the implementation of risk minimization measures for bosentan: a retrospective study	4
Utilizing temporal pattern of adverse event reports to identify potential late-onset adverse events	4
Safety profile of letrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports	4
Hypersensitivity reactions to biologics in chronic rheumatic diseases: prevalence and associated factors	4
The emerging role of Bruton’s tyrosine kinase inhibition in urticaria management	4
Correction	4
A safety review of current monoclonal antibodies used to treat multiple sclerosis	4
Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)	4
Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system	4
Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitors	4
Dementia-related adverse events associated with direct oral anticoagulants use: a real-world, pharmacovigilance study based on the FAERS database	4
Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System	4
Tolerability of rivastigmine transdermal patch in patients with Alzheimer’s disease: a narrative review	4
Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database	4
Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis	4
Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis	4
Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study	4
Non-melanoma skin cancer and other adverse events resulting from antihypertensive drug use: what do we know?	4
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database	4
Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology	4
Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system	4
A cross-sectional study on substandard and falsified medicines (fake or counterfeit drugs) in UK pharmacies during the COVID-19 pandemic	4
Safety assessment of ezetimibe: real-world adverse event analysis from the FAERS database	4